Flputnam Investment Management Co. Has $7.70 Million Stock Position in Abbott Laboratories $ABT

Flputnam Investment Management Co. raised its stake in Abbott Laboratories (NYSE:ABT) by 9.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,829 shares of the healthcare product maker’s stock after acquiring an additional 7,469 shares during the quarter. Flputnam Investment Management Co.’s holdings in Abbott Laboratories were worth $7,697,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ABT. Brighton Jones LLC grew its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC increased its position in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares during the period. United Bank boosted its stake in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after purchasing an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC lifted its position in shares of Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after acquiring an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board grew its position in Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after purchasing an additional 292,547 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ABT. Bank of America decreased their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. BTIG Research upped their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Wells Fargo & Company upped their target price on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. UBS Group cut their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Finally, TD Cowen raised their price target on Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Trading Down 0.5%

NYSE:ABT opened at $108.29 on Friday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a 50-day moving average price of $104.43 and a 200-day moving average price of $100.12. The stock has a market cap of $187.38 billion, a price-to-earnings ratio of 35.05, a P/E/G ratio of 2.02 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same period last year, the business posted $1.26 earnings per share. Abbott Laboratories’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.